Cancer Research AACR Membership  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Carbone, M.
Right arrow Articles by Wong, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Carbone, M.
Right arrow Articles by Wong, M.
[Cancer Research 64, 5518-5524, August 1, 2004]
© 2004 American Association for Cancer Research


Meeting Report

Modern Criteria to Establish Human Cancer Etiology

Michele Carbone1, George Klein2, Jack Gruber3 and May Wong3

1 Cardinal Bernardin Cancer Center, Department of Pathology, Loyola University Chicago, Maywood, Illinois; 2 Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden; and 3 Cancer Etiology Branch, Division of Cancer Biology, National Cancer Institute, Bethesda, Maryland

ABSTRACT

The Cancer Etiology Branch of the National Cancer Institute hosted a workshop, "Validation of a causal relationship: criteria to establish etiology," to determine whether recent technological advances now make it possible to delineate improved or novel criteria for the rapid establishment for cancer causation. The workshop was held in Washington, D.C., December 11–12, 2003, and participants were among the international leaders in the fields of epidemiology, chemistry, biochemistry, microbiology, virology, environmental and chemical carcinogenesis, immunology, pathology, molecular pathology, genetics, oncology, and surgical oncology. There was a general consensus that the rapid identification of human carcinogens and their removal (when possible) or the establishment of specific preventive and therapeutic measures was the most desirable and effective way to have a rapid and positive impact in the fight against cancer. From a clinical perspective, it may be as important to target initiators, cocarcinogens and promoters, if by removing any one of them tumor growth can be prevented. Future studies should focus on interactions among and between different biological, chemical, and physical agents. Analyses of single agents can at times miss their carcinogenic potential when such agents are carcinogenic only in subgroups of individuals because of their genetic background, diet, exposure to other carcinogens, or microbial infection. Epidemiology, molecular pathology (including chemistry, biochemistry, molecular biology, molecular virology, molecular genetics, epigenetics, genomics, proteomics, and other molecular-based approaches), and animal and tissue culture experiments should all be seen as important integrating evidence in the determination of human carcinogenicity. Concerning the respective roles of epidemiology and molecular pathology, it was noted that epidemiology allows the determination of the overall effect of a given carcinogen in the human population (e.g., hepatitis B virus and hepatocellular carcinoma) but cannot prove causality in the individual tumor patient. Molecular pathology cannot determine the overall impact of a carcinogen in the population but can at times prove causality in the individual tumor patient [such as the detection of high-risk human papillomavirus (HPV) in a cervical carcinoma biopsy]. This is possible when molecular techniques have shown that the agent is required for transformation or malignant growth of human cells (such as antisense HPV strategies showing the requirement for the expression of HPV proteins for tumor cell growth) and when there is supportive experimental animal evidence. Ideally, epidemiology and molecular pathology information together with experimental evidence in animals should be available for the most reliable identification of human carcinogens. All sets of data are not always available, and a rapid identification of human carcinogens is in the best public health interest. Swift validation of a causal relationship when followed by a rapid deployment of preventive and therapeutic approaches should lead to a favorable public health impact (such as hepatitis B virus vaccination to prevent hepatocellular carcinoma).




This article has been cited by other articles:


Home page
JNCI J Natl Cancer InstHome page
T. Rampias, C. Sasaki, P. Weinberger, and A. Psyrri
E6 and E7 Gene Silencing and Transformed Phenotype of Human Papillomavirus 16-Positive Oropharyngeal Cancer Cells
J Natl Cancer Inst, March 18, 2009; 101(6): 412 - 423.
[Abstract] [Full Text] [PDF]


Home page
CarcinogenesisHome page
T. V. Bagnyukova, V. P. Tryndyak, B. Montgomery, M. I. Churchwell, A. R. Karpf, S. R. James, L. Muskhelishvili, F. A. Beland, and I. P. Pogribny
Genetic and epigenetic changes in rat preneoplastic liver tissue induced by 2-acetylaminofluorene
Carcinogenesis, March 1, 2008; 29(3): 638 - 646.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. De-Castro Arce, E. Gockel-Krzikalla, and F. Rosl
Retinoic Acid Receptor beta Silences Human Papillomavirus-18 Oncogene Expression by Induction of de Novo Methylation and Heterochromatinization of the Viral Control Region
J. Biol. Chem., September 28, 2007; 282(39): 28520 - 28529.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. U. Dogan, Y. I. Baris, M. Dogan, S. Emri, I. Steele, A. G. Elmishad, and M. Carbone
Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey.
Cancer Res., May 15, 2006; 66(10): 5063 - 5068.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. A. Altomare, C. A. Vaslet, K. L. Skele, A. De Rienzo, K. Devarajan, S. C. Jhanwar, A. I. McClatchey, A. B. Kane, and J. R. Testa
A Mouse Model Recapitulating Molecular Features of Human Mesothelioma
Cancer Res., September 15, 2005; 65(18): 8090 - 8095.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.